In the general news, yet another private spacecraft exploded. This time, an astronaut was killed on board the Virgin Atlantic craft. Apple’s CEO Tim Cook came out as being gay, and in the economy, the Fed finally ended the bond buying free-money era, but left interest rates at zero.
In healthcare business news, Sanofi ousted its CEO. Amgen (AMGN) cut more jobs amidst calls from investors to split the company. Pfizer (PFE) cancelled its partnership with Durect (DRRX) to sell pain drug Remoxy. Lastly, Express Scripts (ESRX) announced that an Abbvie (ABBV) HCV drug could replace Gilead’s (GILD) pricey Sovaldi or Harvoni on the formulary if the Abbvie drug is less costly.
On the data front, Bristol (BMY) posted good data on nivolumab for lung cancer. Shares rose 3%.
From the FDA Sarepta (SRPT) shares imploded when regulatory milestones were pushed back for the Duchenne MD drug eteplirsen. Also Daiichi’s blood thinner, edoxaban, won a panel recommendation for approval.